Modified formulation of some radiolabed anticancer agents for nuclear medicine application /
Manal Magdy Sayed Hassan
Modified formulation of some radiolabed anticancer agents for nuclear medicine application / صياغة مطورة لبعض مضادات السرطان المرقمة اشعاعيا لاستخدامها فى تطبيقات الطب النووى Manal Magdy Sayed Hassan ; Supervised Mohamed Elnabarawi , Abeer Mohamed Amin , Abdulaziz Mohsen Almahallawi - Cairo : Manal Magdy Sayed Hassan , 2020 - 164 P. : charts , facsimiles ; 25cm
Thesis (Ph.D.) - Cairo University - Faculty of Pharmacy - Department of Pharmaceutics
As the mortality due to cancer continues to rise, advances in nanotechnology have significantly become an effective approach for achieving efficient drug targeting to tumor tissues. Toxic chemotherapeutics given in their free form distribute broadly throughout the body, but by redirecting more of the drug dose towards tumor sites, reduced systemic side effects are expected, thus making anticancer treatment safer than conventional approaches . A recent interest in the use of self-assembled nanostructured materials for controlling the release of incorporated agents has been evolved. In the pharmaceutical area, viscous lipid-based systems, such as bicontinuous cubic liquid crystalline phases, offer considerable scope for application as drug delivery systems . Nanocubosomes are nano-structures composed mainly of amphiphilic polar lipid. When this amphiphilic substance dissolved in water with concentration above the critical micelle concentration, it forms micellar aggregations. At higher concentrations, the formed micelles are forced to form cubic structure . Alkylating agents, such as chlorambucil (4-[p-[bis [2-chloroethyl] amino] phenyl]-butanoic acid (CHB), are extensively used in the treatment of neoplastic diseases, such as chronic lymphocytic leukemia, lymphomas, advanced ovarian and breast cancer .However, chlorambucil use is limited by its toxic side effects, including myelotoxicity and neurotoxicity. These adverse profiles, limit the use of optimal doses of chemotherapeutic drug CHB. Consequently, protocols with sub-optimal doses are frequently used, minimizing toxicity and patient suffering but often resulting in inefficient treatment and unsatisfactory prognosis
¹²⁵I-Uridine Anticancer Nanocubosomal
Modified formulation of some radiolabed anticancer agents for nuclear medicine application / صياغة مطورة لبعض مضادات السرطان المرقمة اشعاعيا لاستخدامها فى تطبيقات الطب النووى Manal Magdy Sayed Hassan ; Supervised Mohamed Elnabarawi , Abeer Mohamed Amin , Abdulaziz Mohsen Almahallawi - Cairo : Manal Magdy Sayed Hassan , 2020 - 164 P. : charts , facsimiles ; 25cm
Thesis (Ph.D.) - Cairo University - Faculty of Pharmacy - Department of Pharmaceutics
As the mortality due to cancer continues to rise, advances in nanotechnology have significantly become an effective approach for achieving efficient drug targeting to tumor tissues. Toxic chemotherapeutics given in their free form distribute broadly throughout the body, but by redirecting more of the drug dose towards tumor sites, reduced systemic side effects are expected, thus making anticancer treatment safer than conventional approaches . A recent interest in the use of self-assembled nanostructured materials for controlling the release of incorporated agents has been evolved. In the pharmaceutical area, viscous lipid-based systems, such as bicontinuous cubic liquid crystalline phases, offer considerable scope for application as drug delivery systems . Nanocubosomes are nano-structures composed mainly of amphiphilic polar lipid. When this amphiphilic substance dissolved in water with concentration above the critical micelle concentration, it forms micellar aggregations. At higher concentrations, the formed micelles are forced to form cubic structure . Alkylating agents, such as chlorambucil (4-[p-[bis [2-chloroethyl] amino] phenyl]-butanoic acid (CHB), are extensively used in the treatment of neoplastic diseases, such as chronic lymphocytic leukemia, lymphomas, advanced ovarian and breast cancer .However, chlorambucil use is limited by its toxic side effects, including myelotoxicity and neurotoxicity. These adverse profiles, limit the use of optimal doses of chemotherapeutic drug CHB. Consequently, protocols with sub-optimal doses are frequently used, minimizing toxicity and patient suffering but often resulting in inefficient treatment and unsatisfactory prognosis
¹²⁵I-Uridine Anticancer Nanocubosomal